<DOC>
	<DOCNO>NCT01926977</DOCNO>
	<brief_summary>This study design compare post injection inflammation pain see intravitreal injection Ranibizumab v Aflibercept .</brief_summary>
	<brief_title>Evaluation Pain Inflammation After Injection Lucentis v Eylea Treatment Wet Macular Degeneration</brief_title>
	<detailed_description>This open-label , Phase I-II study post injection pain inflammation intravitreally administer Ranibizumab Aflibercept 100 subject Neovascular Age-Related Macular Degeneration . We enroll treatment experience ( patient treat Lucentis Eylea , Avastin past ) treatment naive patient ( new onset Neovascular AMD history intravitreal injection ) . The treatment experience patient treated intravitreal medication receive past , example , patient treat Lucentis switch Eylea study purpose vice versa . Consented , enrolled subject receive open-label intravitreal injection either 0.5mg Ranibizumab 2mg Aflibercept . A standard intravitreal injection protocol follow . Patients reevaluate 24-48 hour 5-7 day post injection . A non-injecting physician evaluate patient anterior chamber inflammation ; physician blind specific treatment . Anterior chamber inflammation describe cell flare anterior chamber . These evaluate use Standardization Uveitis Nomenclature ( SUN ) work group classification . Pain score evaluate use Numerical Rating Scale . Each patient standard script verbally read visit , ask rate pain base scale .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>1 . Able provide inform consent comply study assessment full duration study 2 . Age &gt; /= 65 year 3 . New onset Neovascular AgeRelated Macular Degeneration ( See No.4 ) 4 . Previously treat Neovascular AgeRelated Macular Degeneration Lucentis Eylea intravitreal injection 5 . Visual Acuity 20/400 well 6 . No history Post injection pain inflammation prior treatment 1 . History Endophthalmitis either eye 2 . Uncontrolled symptomatic Dry Eye Syndrome 3 . History Anterior Posterior Uveitis 4 . History Post injection pain inflammation prior treatment 5 . Recent thromboembolic event ( &lt; 3 month ) 6 . Pregnancy ( positive pregnancy test ) Lactation/Premenopausal woman use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>